GRIFOLS S A/S (GRFS) Given Average Recommendation of “Hold” by Analysts

Shares of GRIFOLS S A/S (NASDAQ:GRFS) have been assigned an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several analysts have recently commented on GRFS shares. BidaskClub lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Santander upgraded GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a report on Tuesday, October 30th. Finally, Zacks Investment Research upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, October 31st.

Shares of GRFS opened at $19.00 on Thursday. GRIFOLS S A/S has a 12 month low of $17.42 and a 12 month high of $24.97. The company has a quick ratio of 1.07, a current ratio of 2.78 and a debt-to-equity ratio of 1.47. The firm has a market cap of $12.65 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 1.24 and a beta of 1.07.

A number of hedge funds have recently modified their holdings of the stock. Northern Trust Corp raised its stake in GRIFOLS S A/S by 4.3% in the 4th quarter. Northern Trust Corp now owns 544,975 shares of the biotechnology company’s stock worth $10,006,000 after acquiring an additional 22,602 shares during the last quarter. Advisor Group Inc. raised its stake in GRIFOLS S A/S by 18.7% in the 4th quarter. Advisor Group Inc. now owns 25,065 shares of the biotechnology company’s stock worth $460,000 after acquiring an additional 3,941 shares during the last quarter. Raymond James & Associates raised its stake in GRIFOLS S A/S by 75.9% in the 4th quarter. Raymond James & Associates now owns 20,090 shares of the biotechnology company’s stock worth $369,000 after acquiring an additional 8,670 shares during the last quarter. Hansberger Growth Investors LP raised its stake in GRIFOLS S A/S by 2.3% in the 4th quarter. Hansberger Growth Investors LP now owns 103,925 shares of the biotechnology company’s stock worth $1,908,000 after acquiring an additional 2,294 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in GRIFOLS S A/S by 45.3% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,799 shares during the last quarter. Institutional investors own 19.57% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Read More: Marijuana Stocks Investing Considerations

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit